BRIEF-Engitix Announces Strategic Collaboration With Gsk To Advance First-In-Class Targets For Liver Fibrosis Regression

GSK

GSK

GSK

0.00

June 8 (Reuters) - GSK plc GSK.L:

  • ENGITIX ANNOUNCES STRATEGIC COLLABORATION WITH GSK TO ADVANCE FIRST-IN-CLASS TARGETS FOR LIVER FIBROSIS REGRESSION

  • ENGITIX: UNDER TERMS, CO IS ELIGIBLE TO GET UP TO £44.5 MILLION IN UPFRONT AND NEAR-TERM PAYMENTS

  • ENGITIX: GSK WILL HAVE OPTION TO LICENSE ASSAYS, DATASETS, AND TARGETS ARISING FROM COLLABORATION

  • ENGITIX: UNDER TERMS, CO ALSO ELIGIBLE FOR UP TO £118 MILLION PER TARGET IN DOWNSTREAM MILESTONE PAYMENTS

Source text: ID:nGNX277H2Z

Further company coverage: GSK.L


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.